Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and Schizophrenia

Joseph P. McEvoy, MD, and Daniel E. Kremens, MD, JD

Tardive dyskinesia (TD), a condition of potentially irreversible abnormal involuntary movements that is associated with dopamine receptor blocking agents (DRBAs) such as antipsychotics, can produce substantial impairment of functioning and diminished quality of life for patients.1 Contrary to expectations, TD has not vanished as the use of second-generation antipsychotics (SGAs) has become more widespread than use of first-generation antipsychotics (FGAs). In fact, expanded drug indications and increased off-label prescription of SGAs have placed more patients than ever at risk for TD.

In this Academic Highlights, Drs McEvoy and Kremens discuss best practices for recognizing early signs of TD through regular screening, educating the patient and family about risk factors, addressing psychosocial concerns related to TD, and selecting new FDA-approved medication—to treat TD.

An individual living with TD described the burden the condition places on his life:

“I hate the thought of being like this forever. . . . Most people are understanding, but it’s the odd moments when I’m in public or a quiet place and the lip smacking becomes noticeable, not to mention the odd sensations in my tongue from constantly rubbing against my bottom teeth.”2

THE IMPORTANCE OF EARLY RECOGNITION AND DIAGNOSIS OF TD

Accurate diagnosis of TD is crucial for potential reversal of symptoms; however, Dr Kremens noted it can present a clinical challenge due to the insidious onset and fluctuating nature of symptoms. Clinicians may underestimate the risk of TD associated with SGA treatment and should review patients’ risk factors and try to prevent TD.2,3 Dr Kremens emphasized that clinicians should discuss risk factors with patients and caregivers (Table 1).4 Regular screening and patient education are important. If patients develop signs of TD, diagnostic tools and criteria should be used.
PSYCHOSOCIAL IMPLICATIONS OF TD

Many patients with schizophrenia and some with severe bipolar disorder demonstrate multiple fixed deficits, which can include negative psychopathology, neurologic soft signs, and a lack of insight into their illness, in addition to...
psychosis and agitation. Tardive dyskinesia is more common and severe in patients with fixed deficits, and these patients tend to be unaware that they have abnormal involuntary movements.

An individual living with TD described her lack of awareness of her abnormal movements:

"With the lip movement, I am completely unaware that I am doing it. . . . I only found out when a coworker asked me about it. . . . I had no idea what she was talking about. I asked some other people and they said: 'Oh, that thing you do with your lips. Sure, I've seen that.'"

Dr McEvoy noted that, in patients with lack of insight into the presence of TD, motivation to treat it is determined primarily by the AIMS results. If the movements are disfiguring or interfere with the patient's basic functioning, clinicians should aggressively treat patients even if they are unaware of the movements or express little distress about them.

Patients with bipolar disorder, especially the milder variants, and patients with recurrent major depression are more likely to achieve sustained remission of their target psychopathology than are patients with schizophrenia. These patients have fewer and less severe deficits and are more likely to be aware of and distressed by abnormal movements.

Dr McEvoy shared that even mild movements should be treated if patients are distressed by them, as they can substantially impact psychosocial functioning. In an interview with the Depression and Bipolar Support Alliance (oral communication, March 2019), a patient described not realizing how noticeable her movements were until she saw herself in a video:

"I went to a Christmas party for church, and the church was going to make a video of all of us there, singing a song so that they could use that as the invitation for another Christmas party. . . . And so I was singing the song “Joy to the World” and then they sent it out by e-mail to everybody in the church. And I opened it with my husband and I was mortified. I was the only one having movements during the song. My hands were flapping up and down with every single word. My husband said I looked like a chicken that was trying to take flight. . . . You know, he helped me find the funny side of it, but . . . I was very embarrassed as well because I knew every member in my church was going to see this."

**FDA-APPROVED MEDICATIONS TO TREAT TD**

Two treatments for TD, which are both novel vesicular monoamine transporter type 2 (VMAT2) inhibitors, have been approved by the FDA: valbenazine and deutetrabenazine (Table 2). According to Dr McEvoy, these new medications can be life changing for individuals with TD who continue to need antipsychotic treatment despite the side effects.

Individuals with TD described the difference that treatment made to them:

"[My doctor] started me on some new medications and experimented with decreasing a few of the medications I was already taking to get the right combination to treat my mental disorder and also help my TD symptoms. As a result, my level of distress has decreased tremendously. I am braver now socially."

"This new treatment has changed my life in ways I never thought it could. I can go in public without fear of being stared at, I can breathe normally, I feel human again. Antipsychotics changed my life, and I can’t imagine my life without them, and now that I have the additional medication, I can’t imagine my life without that either."

---

**Table 2. Differences Between Approved Drug Treatments for Tardive Dyskinesia**

<table>
<thead>
<tr>
<th>Profile</th>
<th>Valbenazine</th>
<th>Deutetrabenazine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dosing frequency</td>
<td>Once daily</td>
<td>Twice daily</td>
</tr>
<tr>
<td>Initial dose</td>
<td>40 mg/d</td>
<td>12 mg/d (in divided doses)</td>
</tr>
<tr>
<td>Recommended dose</td>
<td>80 mg/d</td>
<td>12–48 mg/d (in divided doses)</td>
</tr>
<tr>
<td>Administer with food?</td>
<td>With or without</td>
<td>With</td>
</tr>
<tr>
<td>Cytochrome P450 (CYP) action</td>
<td>CYP2D6, CYP3A4</td>
<td>CYP2D6</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Monoamine oxidase inhibitors, Hypersensitivity to valbenazine</td>
<td>Monoamine oxidase inhibitors, Valbenazine, Reserpine, Tetrabenazine, Hepatic impairment</td>
</tr>
<tr>
<td>Warnings/precautions</td>
<td>Impaired driving ability due to somnolence, QT prolongation, Parkinsonism</td>
<td>Impaired driving ability due to somnolence, QT prolongation, Parkinsonism, Neuroleptic malignant syndrome</td>
</tr>
<tr>
<td>Common adverse events</td>
<td>Somnolence</td>
<td>Nasopharyngitis, Insomnia</td>
</tr>
</tbody>
</table>

Based on Citrome 2018 and package inserts for valbenazine and deutetrabenazine.
**Valbenazine**

Valbenazine received FDA approval for the treatment of TD in 2017 based largely on the positive results of KINECT 3, a phase 3 double-blind randomized controlled trial. In this study,\(^3\) participants (N = 225) with schizophrenia, schizoaffective disorder, or a mood disorder who had moderate or severe TD were randomly assigned in a 1:1:1 ratio to once-daily placebo, valbenazine 40 mg/d, or valbenazine 80 mg/d. About 86% of participants were taking antipsychotics. Least-squares mean change in AIMS dyskinesia scores was \(-3.2\) for the 80-mg/d group, \(-1.9\) for the 40-mg/d group, and \(-0.1\) for the placebo group (\(P < .001\) for 80 mg/d vs placebo). The 1-year KINECT 3 extension study\(^3\) demonstrated long-term efficacy, safety, and tolerability of valbenazine for the treatment of TD.

Dr Kremens noted that the only adverse effect with \(\geq 5\%\) incidence for valbenazine and occurring \(\geq 2\) times than with placebo was somnolence/fatigue/sedation, with rates of 10.9% for valbenazine (both doses) and 4.2% for placebo, resulting in a number needed to harm of 15 (95% CI, 9–52).\(^2\) The product label has a precaution against driving until the drug's sleep effects on the patient are known.\(^2\) Besides somnolence, Dr Kremens identified QT prolongation as the other labeled precaution. Other adverse effects include anticholinergic effects, balance problems, headache, gastrointestinal issues, and arthralgia.

Valbenazine is slowly metabolized, allowing for once-daily dosing, with or without food, starting at 40 mg and increasing to 80 mg after 1 week.\(^2\)

**Deutetrabenazine**

Deutetrabenazine received FDA approval for the treatment of TD in 2017 on the basis of results from 2 double-blind randomized controlled trials: the phase 2/3 trial ARM-TD and the phase 3 trial AIM-TD.\(^2\) In both studies, Dr Kremens noted that patients could continue the use of DRBAs or antidepressants as long as there had been no recent change in these medications.

The ARM-TD study\(^3\) examined a flexible dose of deutetrabenazine starting at 12 mg/d (6 mg twice daily) and titrated weekly by 6 mg/d, if required, versus placebo in 117 patients with moderate to severe TD. The mean total daily dose was 38.8 mg/d at the end of the 12-week study period. AIMS scores decreased significantly in the deutetrabenazine group versus the placebo group (\(-3.0\) vs \(-1.6; P = .003\)) and \(-3.3\) (\(P < .001\) for 80 mg/d vs placebo). The 1-year KINECT 3 extension study\(^2\) demonstrated long-term efficacy, safety, and tolerability of deutetrabenazine for the treatment of TD.

Dr Kremens noted that patients could continue the use of DRBAs or antidepressants as long as there had been no recent change in these medications.

The ARM-TD study\(^3\) examined a flexible dose of deutetrabenazine starting at 12 mg/d (6 mg twice daily) and titrated weekly by 6 mg/d, if required, versus placebo in 117 patients with moderate to severe TD. The mean total daily dose was 38.8 mg/d at the end of the 12-week study period. AIMS scores decreased significantly in the deutetrabenazine group versus the placebo group (\(-3.0\) vs \(-1.6; P = .003\)) and \(-3.3\) (\(P < .001\) for 80 mg/d vs placebo). The 1-year KINECT 3 extension study\(^2\) demonstrated long-term efficacy, safety, and tolerability of deutetrabenazine for the treatment of TD.

Dr Kremens noted that patients could continue the use of DRBAs or antidepressants as long as there had been no recent change in these medications.

The ARM-TD fixed-dose study\(^4\) randomized 298 patients 1:1:1:1 to receive placebo or deutetrabenazine 12, 24, or 36 mg/d (divided in 2 doses) for 8 weeks after a 4-week titration period. Least-squares mean AIMS scores improved by \(-3.2\) (\(P = .003\)) and \(-3.3\) (\(P = .001\)) in the groups receiving deutetrabenazine 24 and 36 mg/d, respectively, compared with \(-1.4\) for placebo.

Dr Kremens shared that deutetrabenazine was well tolerated, with low rates of side effects in both ARM-TD and AIM-TD.\(^3,4\) The adverse effects that occurred in \(\geq 4\%\) of participants taking deutetrabenazine and at a greater rate than with placebo were nasopharyngitis and insomnia,\(^2\) with number needed to harm values of 50 (not significant) and 34 (95% CI, 18–725), respectively.\(^2\) Depression/dysthymia and akathisia/restlessness also occurred more often than with placebo.\(^2\)

Prescribing information\(^2\) states that the use of deutetrabenazine in combination with other drugs known to prolong QTc may result in clinically significant QT prolongations. For patients requiring deutetrabenazine doses greater than 24 mg/d and who are taking other drugs known to prolong QTc, assess the QTc interval before and after increasing the dose of deutetrabenazine or the other drugs.

Deutetrabenazine is dosed twice daily, is titrated typically over several weeks, and should be taken with food, explained Dr Kremens.\(^2\)

### Academics Highlights

- Differentiate between the 2 FDA-approved agents for TD.
- Treat patients who have TD with evidence-based agents.
- Discuss risk factors and early signs of TD with patients and caregivers.
- Avoid prescribing first-generation antipsychotics.
- Screen patients for signs of TD during routine appointments.
- Recognize the social and occupational impact of TD symptoms in patients who are aware of and distressed by them.
- Treat patients who have TD with evidence-based agents.
- Differentiate between the 2 FDA-approved agents for TD.
- Follow recommended administration, titration, and monitoring of medications for TD.

### Case Practice Question

**Discussion of the best response can be found at the end of the activity.**

**Case 2.** James is a 27-year-old man who was diagnosed with schizophrenia at age 18 years. He has been treated with 5 mg at bedtime of haloperidol for the past 5 years with no relapses and no distressing or intrusive psychotic symptoms. He lives independently with a roommate and has a part-time job stacking shelves. He has gradually developed increasingly apparent spontaneous movements in his face and hands over the past 6 months; you diagnose these as tardive dyskinesia. His roommate and his employer have asked about the movements, and James is concerned that he may lose his job. A trial of pyridoxine 50 mg twice a day has not decreased the movements. The intervention with the greatest likelihood to suppress the movements with the least side effect burden is:

a. Increase the haloperidol to 10 mg at bedtime.

b. Add benztropine 2 mg daily.

c. Increase the pyridoxine dose to 200 mg twice a day.

d. Begin treatment with a VMAT2 inhibitor.
Case 1: Preferred response is b.
HIV positivity is a risk factor for developing TD. Other risk factors include older age, female sex, longer duration and higher doses of DRBAs, treatment with FGAs, preexisting mood disorder, cognitive disturbance, alcohol or substance abuse, diabetes, early occurrence of extrapyramidal symptoms, and African American ethnicity—none of which apply to Tom.

Case 2: Preferred response is d.
Valbenzine and deutetrabenazine are both novel VMAT2 inhibitors approved by the FDA to treat TD. James continues to need antipsychotic treatment, which has been effective in treating his schizophrenia; therefore, he is an optimal candidate for the approved VMAT2 inhibitors.

Published online: January 28, 2020.
Disclosure of off-label usage: The chair has determined that, to the best of his knowledge, benzotropine is not approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.

REFERENCES
25. Citrome L. Valbenzine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication—what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2017;71(7):i13030.
1. Shirley is a 72-year-old white woman with a major depressive episode that has been resistant to treatment with only an antidepressant. You decide to add a second-generation antipsychotic (SGA) as adjunctive therapy. Shirley’s medical history is notable for well-controlled diabetes. You should do all of the following for Shirley except:
   a. Warn her that she is at an increased risk of developing tardive dyskinesia (TD) because of her age, sex, and diabetes.
   b. Warn her that she is at an increased risk of developing TD because of her mood disorder and her ethnicity.
   c. Screen her for abnormal movements before starting the SGA and then at least twice a year.
   d. Use the SGA conservatively (at a low dose and only as long as necessary for remission of the episode).

2. Marilyn is a 52-year-old woman who has experienced recurrent episodes of major depressive disorder (MDD) since the age of 24 years. Treatment with a selective serotonin reuptake inhibitor and a dopamine receptor partial agonist has kept her in remission for the past 4 years. On a routine AIMS examination that is conducted every 6 months, “mild” movements of her tongue and of her hands appear during activation maneuvers. Marilyn reports that a co-worker has asked about these movements during the past 3 months. Your best advice to her would be:
   a. Because the dopamine receptor partial agonist dose is low, the likelihood that these movements will become more severe is very low.
   b. If the movements become more severe, the dopamine receptor partial agonist can be discontinued with little or no risk of recurrence of MDD, and the movements will disappear.
   c. There is a high likelihood that use of a VMAT2 inhibitor will substantially reduce the severity of these movements to a level not detectable by others.
   d. The use of a VMAT2 inhibitor will increase the likelihood of an episode of MDD even if she continues taking the prescribed antidepressant and dopamine receptor partial agonist.

3. Michael is a 37-year-old man with schizophrenia who lives in a personal care home. He has substantial deficits in cognitive function, volition, and expression. He also has TD that has gradually increased in severity, with ratings of “moderate” for his jaw and tongue movements. What is the most compelling reason to begin treatment with a VMAT2 inhibitor?
   a. His keen awareness of the movements and request for relief
   b. The increasing frequency with which he has been choking when he eats or drinks
   c. The complaints from other residents of the home about his movements
   d. The frequency with which the staff need to launder his clothes because of his persistent drooling